Athena Athena

X
[{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Paratek Announces License Grant to Almirall for SEYSARA\u00ae (sarecycline) for Greater China Region","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$285.0 million","upfrontCash":"$20.0 million","newsHeadline":"Paratek Pharmaceuticals Announces Initiation of Funding from BARDA ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Presenting New Data on NUZYRA\u00ae (Omadacycline) at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Hosting Investor Webinar with Corporate Updates and KOL and Patient Advocate Presentations on M. abscessus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$38.0 million","upfrontCash":"Undisclosed","newsHeadline":"Paratek Pharmaceuticals Announces First BARDA Project BioShield Procurement of NUZYRA\u00ae (omadacycline) Valued at ~$38 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Presenting New Data for NUZYRA\u00ae (omadacycline) at IDWeek 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Announces the Publication of Data From an Investigator-Initiated Study of NUZYRA\u00ae (omadacycline) in a Hollow Fiber System Model Against Pulmonary Mycobacterium avium Complex","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Zai Lab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals' NUZYRA Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$284.0 million","upfrontCash":"Undisclosed","newsHeadline":"Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA\u00ae (omadacycline) Under BARDA Project BioShield Contract","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA\u00ae (omadacycline) under BARDA Project BioShield","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$304.0 million","upfrontCash":"Undisclosed","newsHeadline":"Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA\u00ae (omadacycline) under BARDA Project BioShield Contract","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Announces Inclusion of Nuzyra\u00ae (omadacycline) in China's National Reimbursement Drug List (NRDL)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Axplora","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novasep And Paratek Enhance Collaboration to Manufacture Omadacycline (NUZYRA\u00ae), A Novel Tetracycline-Class Antibiotic for The Treatment of Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$287.0 million","upfrontCash":"Undisclosed","newsHeadline":"Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$304.0 million","upfrontCash":"Undisclosed","newsHeadline":"Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$462.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gurnet Point Capital and Novo Holdings A\/S Complete Acquisition of Paratek Pharmaceuticals, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Paratek Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The proceeds from the acquisition will advance the commercialization of Nuzyra (omadacycline), a tetracycline antibiotic, indicated for the treatment of adult patients with community-acquired bacterial pneumonia, and support the development of additional therapies.

            Lead Product(s): Omadacycline

            Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gurnet Point Capital

            Deal Size: $462.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition September 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement aims to support the development of omadacycline for post-exposure prophylaxis and pulmonary anthrax and the US-based commercial manufacturing of Nuzyra, a novel once-daily antibiotic approved for the treatment of community-acquired bacterial pneumonia and ABSSSI.

            Lead Product(s): Omadacycline

            Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: $304.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement July 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Nuzyra (omadacycline tosylate) is a novel antibiotic which binds to the 30S ribosomal subunit and blocks protein synthesis and is available for the treatment of of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

            Lead Product(s): Omadacycline

            Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The proceeds from the acquisition will advance the commercialization of Nuzyra (omadacycline), a tetracycline antibiotic, indicated for the treatment of adult patients with community-acquired bacterial pneumonia, and support the development of additional therapies.

            Lead Product(s): Omadacycline

            Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gurnet Point Capital

            Deal Size: $287.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition June 06, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Nuzyra (omadacycline tosylate) is a novel antibiotic which binds to the 30S ribosomal subunit and blocks protein synthesis, available for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

            Lead Product(s): Omadacycline

            Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 19, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NUZYRA® (omadacycline) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

            Lead Product(s): Omadacycline

            Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: $304.0 million Upfront Cash: Undisclosed

            Deal Type: Funding January 05, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NUZYRA® (omadacycline) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

            Lead Product(s): Omadacycline

            Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 19, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, BARDA will award initial funding for the development of NUZYRA (omadacycline tosylate) for the treatment of pulmonary anthrax and the purchase of an initial 2,500 treatment courses of NUZYRA to add to the current SNS.

            Lead Product(s): Omadacycline

            Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: $284.0 million Upfront Cash: Undisclosed

            Deal Type: Partnership October 31, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NUZYRA ® (omadacycline tosylate) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

            Lead Product(s): Omadacycline

            Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 26, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

            Lead Product(s): Omadacycline

            Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Zai Lab

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY